Dr. Reddy's posts lower revenue and profit for quarter ended September 2026
SEC 6-K filing shows the drugmaker's Q2 FY27 revenue and profit both declined from a year earlier, with a Semaglutide inventory charge and a CAR-T asset sale noted.
SEC filing